A standalone M&A transaction to acquire Deciphera Pharmaceuticals’ pharmaceutical pipeline, including QINLOCK® and Vimseltinib, as well as its development and commercial networks in the US and Europe, thereby expanding the company’s direct sales capabilities and product revenue in those markets. This also includes approval of ROMVIMZA after the acquisition and its contribution to product revenue for the full fiscal year.